Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Deepak-Jotwani"

5 News Found

Indian API companies to grow by 7-8% and operating profit margin to improve to 12-14% in FY2025: ICRA
Opinion | August 14, 2024

Indian API companies to grow by 7-8% and operating profit margin to improve to 12-14% in FY2025: ICRA

Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024


Indian pharmaceutical companies to grow by 6-7% in FY2023: ICRA
News | July 16, 2022

Indian pharmaceutical companies to grow by 6-7% in FY2023: ICRA

ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.


Indian pharma growth likely to moderate in FY23: ICRA
News | April 07, 2022

Indian pharma growth likely to moderate in FY23: ICRA

Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23


Outlook for the Indian Pharma Industry remains stable for this year
Opinion | January 13, 2022

Outlook for the Indian Pharma Industry remains stable for this year

The stability is led by healthy demand in the domestic and emerging markets


Domestic and emerging markets will drive pharma growth: ICRA
News | January 04, 2022

Domestic and emerging markets will drive pharma growth: ICRA

Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters